British Journal of Clinical Pharmacology
January 2009
Lineke Zuurman, Annelies E Ippel, Eduard Moin et al.
An increasing number of novel therapeutic agents are targeted at cannabinoid receptors. Drug development programmes of new cannabinoid drugs may be facilitated by the identification of useful biomarkers. This systemic literature review aims to assess the usefulness of direct biomarkers for the effects of cannabis and tetrahydrocannabinol (THC) in healthy volunteers. One hundred and sixty-five...
European Psychiatry
2009
C. Morgan
Cannabis contains a myriad of different chemicals, more than 60 of which are unique to the plant and called cannabinoids. The main psychoactive ingredient is delta9-tetrahydrocannabinol (THC) and this produces the effects that users seek (Curran et al., 2002 Psychopharmacology 164: 61-70). When given intravenously to healthy humans, THC produces psychotic-like and anxiogenic effects (D’Souza et...
European Psychiatry
2009
Rebecca Kuepper, Inez Myin-Germeys, M. Konings et al.
2 citations
Frequent use of cannabis has been associated with poor outcome in patients with psychosis or schizophrenia, and research has become more and more interested in the question whether cannabis may actually cause psychosis or schizophrenia. Since only a minority of cannabis users eventually develops psychosis or schizophrenia, cannabis is suggested to be a component cause, potentially interacting...
L information psychiatrique
2009
Lisa Blecha, Amine Benyamina
Résumé En France, le cannabis est le produit illicite le plus consommé. En 2005, 3,9 millions de français entre 15 et 75 ans avaient au moins un usage dans l’année. Le cannabis est utilisé depuis les temps anciens dans la pharmacopée médicale pour ses propriétés antispasmodiques et analgésiques, d’où la perception courante d’un remède naturel. Les études ont montré que le cannabis est associé...
European Psychiatry
2009
M. Arendt
Background:Both the ICD-10 and the DSM-IV operate with a diagnosis of cannabis-induced psychotic disorder. Despite this, the diagnosis is controversial.A number of studies have shown that cannabis can induce short-lived psychotic symptoms, and that this could depend on factors such as genetic predisposition. To qualify for a diagnosis of ‘cannabis-induced psychosis’, however, the symptoms must...
European Psychiatry
2009
I.B. Crome
Aim:This contribution will explore UK-based research developments in substance misuse and mental illness over the last 20 years.Methods:The main body of work revolves around research largely, but not only, funded by the Department of Health from the late 1990s. Early research revolved around alcohol, especially alcoholic hallucinosis: the relationship with schizophrenia-like illness was...
Archives of General Psychiatry
2009
Paolo Fusar‐poli, José A. Crippa, Sagnik Bhattacharyya et al.
461 citations
CONTEXT: Cannabis use can both increase and reduce anxiety in humans. The neurophysiological substrates of these effects are unknown. OBJECTIVE: To investigate the effects of 2 main psychoactive constituents of Cannabis sativa (Delta9-tetrahydrocannabinol [Delta9-THC] and cannabidiol [CBD]) on regional brain function during emotional processing. DESIGN: Subjects were studied on 3 separate...
European Psychiatry
2009
Paul D. Morrison, Shitij Kapur, R. Murray
1 citation
It has long been known that cannabis can elicit an acute psychotic reaction. Recent work shows that, of the 60 cannabinoid molecules in the plant, delta-9-tetrahydrocannibinol is responsible for the central effects of cannabis. Here we aimed to investigate, in more detail, the psychological effects of synthetic intravenous THC in healthy subjects. Over 2 experimental sessions, participants...
Biological Psychiatry
December 1, 2008
Stefan Borgwardt, Paul Allen, Sagnik Bhattacharyya et al.
This study examined the effect of Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) on brain activation during a motor inhibition task. Functional magnetic resonance imaging and behavioural measures were recorded while 15 healthy volunteers performed a Go/No-Go task following administration of either THC or CBD or placebo in a double-blind, pseudo-randomized, placebo-controlled repeated...
European Neuropsychopharmacology
November 2008
Maria Ellgren, A Artmann, O Tkalych et al.
Adolescence is a critical phase of active brain development often characterized by the initiation of marijuana (Cannabis sativa) use. Limited information is known regarding the endogenous cannabinoid system of the adolescent brain as well as related neurotransmitters that appear sensitive to cannabis exposure. We recently observed that adult rats pre-exposed to Delta-9-tetrahydrocannabinol...